Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LISATA THERAPEUTICS, INC. Director's Dealing 2015

May 21, 2015

34931_dirs_2015-05-21_4fa4c816-0150-47b4-8ad3-f8930613b390.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeoStem, Inc. (NBS)
CIK: 0000320017
Period of Report: 2015-05-19

Reporting Person: Preti Robert A (See Remarks)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-05-19 Common stock, $0.001 par value A 520 Acquired 190954 Direct

Footnotes

F1: Represents the Reporting Person's one third percentage of the contingent shares of common stock, par value $0.001 per share, of NeoStem, Inc. (the "Company"), which was issued in accordance with the terms of the Agreement and Plan of Merger, dated July 13, 2011, between the Company and Amorcyte, Inc. (the "Merger Agreement").